Oct. 24, 2019 | News

rMark Bio and West Monroe enter multi-year strategic partnership to accelerate the adoption of AI in life sciences

This partnership allows West Monroe to pair an AI platform with deep business and technical expertise to help life science companies more readily utilize data intelligence to build competitive advantage and transform the way medical affairs and commercial teams engage with stakeholders. 

Today, pharmaceutical companies utilize rMark Bio’s platform to analyze data from multiple external and internal sources in order to understand key stakeholder behaviors and beliefs. Utilizing machine learning, advanced data analytics, and human-centered design, this understanding produces actionable tasks and recommendations about how organizations can best engage with key stakeholders to drive successful outcomes.

“While AI holds significant opportunity, organizations often struggle to effectively implement the technology in a way that delivers real, repeatable value,” said Will Hinde, Managing Director of West Monroe’s Healthcare and Life Sciences practice. “Our mission is to make Medical Affairs and Commercial a competitive differentiator for our clients.”

Our partnership with rMark Bio is directly in line with that value orientation. West Monroe’s full suite of management consulting capabilities and best-in-class digital strategy and transformation, customer experience and engagement, and data and advanced analytics expertise will support the implementation and optimization of rMark Bio’s platform as organizations seek to address the key trends impacting the Life Sciences industry.

“Our intent is to partner with innovative companies that can accelerate how we bring value to clients,” said Tyson Hartman, Senior Director of Strategic Partners & Innovation at West Monroe. “And rMark Bio is a perfect example of that kind of partner.”   

 

Explore our latest news & events